This inventor holds 4 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Heidelberg Immunotherapeutics Gmbh, Heiselberg Immunotherapeutics Gmbh, Lutana Gmbh. Active years: 2014-2022.
Location History:
- Wilhelmsfeld, DE (2014)
- Mannheim, DE (2017 - 2022)
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 1 Years Active: 2014-2022
Title: Michaela Arndt: Innovator in Antibody and Molecular Delivery Technologies
Introduction
Michaela Arndt is a prominent inventor based in Mannheim, Germany. She has made significant contributions to the fields of immunotherapy and molecular delivery systems. With a total of 4 patents, her work focuses on innovative solutions for treating viral infections and enhancing cellular delivery mechanisms.
Latest Patents
One of her latest patents is titled "Topical application for an anti-HSV antibody." This invention describes an anti-HSV antibody or an antigen-binding fragment for use in treating acute infections caused by HSV-1 or HSV-2. The antibody is designed for topical administration and is included in a pharmaceutical composition with an effective amount of the antibody and at least one pharmaceutically acceptable excipient.
Another notable patent is "Construct for the delivery of a molecule into the cytoplasm of a cell." This invention outlines a construct that includes a targeting moiety, a fusogenic moiety derived from dengue virus glycoprotein E, and a molecule intended for delivery into the cytoplasm of a cell. The patent also describes a pharmaceutical composition and a kit that facilitate the delivery of therapeutic and detectable moieties into cells.
Career Highlights
Michaela has worked with several companies, including Lutana GmbH and Heidelberg Immunotherapeutics GmbH. Her experience in these organizations has allowed her to develop and refine her innovative ideas in the field of biotechnology.
Collaborations
Michaela has collaborated with notable professionals in her field, including Jürgen Krauss and Michael Roggendorf. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Michaela Arndt is a trailblazer in the development of antibody therapies and molecular delivery systems. Her innovative patents and collaborations highlight her commitment to advancing medical science and improving treatment options for viral infections.